LENZ Therapeutics, Inc. - Common Stock (NQ:LENZ)

4.230 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 15, 2026 Add to My Watchlist

Price and Volume

Volume	137
Open	4.230
Bid (Size)	4.240 (200)
Ask (Size)	4.350 (300)
Prev. Close	4.230
Today's Range	4.230 - 4.230
52wk Range	4.205 - 50.40
Shares Outstanding	58,102,949
Dividend Yield	340.90%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

September 15, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

September 08, 2026

From Pomerantz LLP

Via GlobeNewswire

Performance

YTD	-73.6%	-73.6%
1 Month	-11.7%	-11.7%
3 Month	-35.1%	-35.1%
6 Month	-66.2%	-66.2%
1 Year	-89.4%	-89.4%

More News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

September 01, 2026

From Pomerantz LLP

Via GlobeNewswire

LENZ Therapeutics (LENZ) Q2 2026 Earnings Call Transcript ↗

August 19, 2026

Via The Motley Fool

LENZ Therapeutics (NASDAQ:LENZ) Q1 Report Shows Revenue Beat But Deepening Losses Sink Stock ↗

May 11, 2026

Via Chartmill

LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q4 Revenue Miss and Wider Loss Following VIZZ Launch ↗

March 24, 2026

Via Chartmill

LENZ Therapeutics Q2 Earnings Call Highlights ↗

August 11, 2026

Via MarketBeat

LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

August 11, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026

August 04, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia

July 06, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand

June 24, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

June 07, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

Alpha Wave Global Reduces RadNet Stake, According to Recent SEC Filing ↗

June 02, 2026

Via The Motley Fool

Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing ↗

May 27, 2026

Via The Motley Fool

LENZ Therapeutics to Participate in Upcoming Investor Conferences

May 26, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics Q1 Earnings Call Highlights ↗

May 11, 2026

Via MarketBeat

Lenz (LENZ) Q1 2026 Earnings Call Transcript ↗

May 11, 2026

Via The Motley Fool

LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 11, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom

April 20, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week ↗

March 27, 2026

Via The Motley Fool

Why Lenz Therapeutics Stock Crashed Today ↗

March 24, 2026

Via The Motley Fool

LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

March 24, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

Top Wall Street Forecasters Revamp LENZ Therapeutics Expectations Ahead Of Q4 Earnings ↗

March 23, 2026

Via Benzinga

LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026

March 17, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia

March 10, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is LENZ Therapeutics, Inc. - Common Stock publicly traded?

Yes, LENZ Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does LENZ Therapeutics, Inc. - Common Stock trade on?

LENZ Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for LENZ Therapeutics, Inc. - Common Stock?

The ticker symbol for LENZ Therapeutics, Inc. - Common Stock is LENZ on the Nasdaq Stock Market

What is the current price of LENZ Therapeutics, Inc. - Common Stock?

The current price of LENZ Therapeutics, Inc. - Common Stock is 4.230

When was LENZ Therapeutics, Inc. - Common Stock last traded?

The last trade of LENZ Therapeutics, Inc. - Common Stock was at 09/15/26 04:00 PM ET

What is the market capitalization of LENZ Therapeutics, Inc. - Common Stock?

The market capitalization of LENZ Therapeutics, Inc. - Common Stock is 245.78M

How many shares of LENZ Therapeutics, Inc. - Common Stock are outstanding?

LENZ Therapeutics, Inc. - Common Stock has 246M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.